Immuno-Oncology drugs lead Japanese clinical trials, 2012-2016

7th September 2017 (Last Updated September 7th, 2017 09:46)

As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of the clinical trials initiated in Japan.

As part of our series of white papers tracking clinical trials activity across the world, GlobalData recently compiled a summary of the clinical trials initiated in Japan.

GlobalData captured records of 8,615 clinical trials across all diseases and phases that had a start date between 1 January 2012 and 31 December 2016.

Out of the most investigated drugs in industry-sponsored clinical trials, the top three were nivolumab, pembrolizumab, and durvalumab. These were followed by esaxerenone, atezolizumab, bevacizumab, ipilimumab, rivaroxaban, avelumab, vonoprazan, aflibercept, adalimumab, and lascufloxacin.

The majority of the trials initiated for these drugs were Phase III trials, closely followed by Phase II and Phase IV trials, as shown in Figure 1. Immuno-oncology drugs nivolumab and pembrolizumab topped the drugs used in industry-sponsored clinical trials in Japan. The overall dominance of monoclonal antibodies in clinical trials was clearly evident, with eight out of the thirteen top drugs being monoclonal antibodies.

Figure 1: Top Drugs Investigated in Japanese Clinical Trials